





TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Cocco E, et al. Cancer Discov. 2020;CD-20-0571



Type I kinase inhibitors

Type II kinase inhibitors



ATP, adenosine triphosphate; TRK, tropomyosin receptor kinase; WT, wild-type

This content is supported by an Independent Educational Grant from Bayer

For more information please visit: www.ntrkconnect.info

December 2020